Abstract
Nitric oxide (NO) plays a critical role in acute and
chronic inflammation. NO’s contributions to cancer are of particular interest
due to its context-dependent bioactivities. For example, immune cells initially
produce cytotoxic quantities of NO in response to the nascent tumor. However,
it is believed that this fades over time and reaches a concentration that
supports the tumor microenvironment (TME). These complex dynamics are further
complicated by other factors, such as diet and oxygenation, making it
challenging to establish a complete picture of NO’s impact on tumor progression.
Although many activity-based sensing (ABS) probes for NO have been developed,
only a small fraction have been employed in vivo and fewer yet are
practical in cancer models where the NO concentration is < 200 nM. To overcome
this outstanding challenge, we have developed BL660-NO, the first ABS
probe for NIR bioluminescence imaging of NO in cancer. Owing to the low intrinsic
background, high sensitivity, and deep tissue imaging capabilities of our
design, BL660-NO was successfully employed to visualize endogenous NO
in cellular systems, a human liver metastasis model, and a murine breast cancer
model. Importantly,
its exceptional performance facilitated the design of a dietary study to examine
the impact of NO on the TME by varying the intake of fat. BL660-NO provides
the first direct molecular evidence that intratumoral NO becomes elevated in mice
fed a high-fat diet who became obese with larger tumors compared to control
animals on a low-fat diet. These results indicate that an inflammatory diet can
increase NO production via recruitment of macrophages and overexpression of iNOS which
in turn can drive tumor progression.
Content

Supplementary material
